Balance Wealth
DNA icon

Balance Wealth’s Ginkgo Bioworks DNA Stock Holding History

Balance Wealth’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$77 Buy
+6
New +$49 ﹤0.01% 958

Other funds holding DNA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Erste Asset Management
Erste Asset Management Vienna, Austria $13.7B AUM 40.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
J.M. Forbes & Co
J.M. Forbes & Co Boston, Massachusetts $1.33B AUM 21.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Balance Wealth's DNA Position: Q3 2026 in Review

Balance Wealth opened a new position in Ginkgo Bioworks (DNA) in Q3 2026: 6 shares worth $77. The stake represents ﹤0.01% of the portfolio and ranks #958 among its holdings.

128 funds tracked by Wall St. Rank hold DNA as of Q3 2026.

  • Balance Wealth held 6 shares of Ginkgo Bioworks worth $77 as of Q3 2026.
  • Ginkgo Bioworks was a new Balance Wealth position in Q3 2026.
  • Ginkgo Bioworks made up ﹤0.01% of Balance Wealth's portfolio in Q3 2026, its #958 holding.
  • 128 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2026.

Based on Balance Wealth's 13F filing for Q3 2026, filed 27 Oct 2026.